Spero Therapeutics Inc Total Assets
Spero Therapeutics Inc total assets. Based on the latest financial reports, Spero Therapeutics Inc (SPRO) holds total assets worth $68.92 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Spero Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Spero Therapeutics Inc (2015–2025)
Total assets of Spero Therapeutics Inc from 2015 to 2025. This chart illustrates how Spero Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See SPRO stock price for real-time trading data and today's change.
Spero Therapeutics Inc - Asset Composition Analysis
Spero Therapeutics Inc Total Assets Breakdown (December 2025)
Spero Therapeutics Inc total assets breakdown as of December 2025. Spero Therapeutics Inc's total assets of $68.92 Million consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.4% |
| Accounts Receivable | $25.39 Million | 36.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Spero Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SPRO working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Spero Therapeutics Inc's current assets represent 97.6% of total assets in 2025, an increase from 83.4% in 2015.
- Cash Position: Cash and equivalents constituted 58.4% of total assets in 2025, down from 79.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 36.8% of total assets.
Spero Therapeutics Inc Competitors by Total Assets
Key competitors of Spero Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Spero Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.59 | 2.19 | 7.29 |
| Quick Ratio | 7.59 | 2.19 | 7.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $58.42 Million | $58.20 Million | $111.73 Million |
Spero Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Spero Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.51 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -37.7% |
| Total Assets | $68.92 Million |
| Market Capitalization | $60.22 Million USD |
Valuation Analysis
Near Book Valuation: The market values Spero Therapeutics Inc's assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Spero Therapeutics Inc's assets decreased by 37.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Spero Therapeutics Inc (2015–2025)
The table below shows the annual total assets of Spero Therapeutics Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $68.92 Million | -37.65% |
| 2024-12-31 | $110.54 Million | -39.39% |
| 2023-12-31 | $182.39 Million | +46.14% |
| 2022-12-31 | $124.80 Million | -27.05% |
| 2021-12-31 | $171.07 Million | +11.48% |
| 2020-12-31 | $153.45 Million | +44.62% |
| 2019-12-31 | $106.10 Million | -17.75% |
| 2018-12-31 | $129.01 Million | +38.01% |
| 2017-12-31 | $93.48 Million | +578.76% |
| 2016-12-31 | $13.77 Million | +91.92% |
| 2015-12-31 | $7.18 Million | -- |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more